Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
Publications
Publications
  • October 2009 (Revised July 2013)
  • Case
  • HBS Case Collection

Gilead Sciences, Inc.: Access Program

By: V. Kasturi Rangan and Katharine Lee
  • Format:Print
  • | Language:English
  • | Pages:25
ShareBar

Abstract

Gilead Sciences, the U.S. leader in HIV/AIDS medicines, with global sales of $5.4 billion in 2009, had undertaken several innovative actions to make its anti-viral products available to over 100 low- and middle-income countries. Having reached nearly 680,000 patients by the middle of 2009, the company's senior managers contemplated how to reach 2 million patients by 2012.

Keywords

Health Care and Treatment; Emerging Markets; Product; Sales; Competitive Strategy; Biotechnology Industry; Pharmaceutical Industry

Citation

Rangan, V. Kasturi, and Katharine Lee. "Gilead Sciences, Inc.: Access Program." Harvard Business School Case 510-029, October 2009. (Revised July 2013.)
  • Educators
  • Purchase

About The Author

V. Kasturi Rangan

Marketing
→More Publications

Related Work

    • October 2009 (Revised July 2013)
    • Faculty Research

    Gilead Sciences, Inc.: Access Program

    By: V. Kasturi Rangan and Katharine Lee
Related Work
  • Gilead Sciences, Inc.: Access Program By: V. Kasturi Rangan and Katharine Lee
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College.